Identification and Validation of a Two-gene Expression Index for Subtype Classification and Prognosis in Diffuse Large B-Cell Lymphoma

Overview

Journal Sci Rep

Specialty Science

Date 2015 May 6

PMID 25940947

Citations 11

Authors

Qinghua Xu

Cong Tan

Shujuan Ni

Qifeng Wang

Fei Wu

Fang Liu

Xun Ye

Xia Meng

Weiqi Sheng

Xiang Du

Affiliations

Soon will be listed here.

Abstract

The division of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes based on gene expression profiling has proved to be a landmark in understanding the pathogenesis of the disease. This study aims to identify a novel biomarker to facilitate the translation of research into clinical practice. Using a training set of 350 patients, we identified a two-gene expression signature, "LIMD1-MYBL1 Index", which is significantly associated with cell-of-origin subtypes and clinical outcome. This two-gene index was further validated in two additional dataset. Tested against the gold standard method, the LIMD1-MYBL1 Index achieved 81% sensitivity, 89% specificity for ABC group and 81% sensitivity, 87% specificity for GCB group. The ABC group had significantly worse overall survival than the GCB group (hazard ratio = 3.5, P = 0.01). Furthermore, the performance of LIMD1-MYBL1 Index was satisfactory compared with common immunohistochemical algorithms. Thus, the LIMD1-MYBL1 Index had considerable clinical value for DLBCL subtype classification and prognosis. Our results might prompt the further development of this two-gene index to a simple assay amenable to routine clinical practice.

Citing Articles

Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting.

Decruyenaere P, Daneels W, Morlion A, Verniers K, Anckaert J, Tavernier J Int J Mol Sci. 2024; 25(18).

PMID: 39337470 PMC: 11432451. DOI: 10.3390/ijms25189982.

Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.

Ma D, Ma Y, Ma Y, Liu J, Gu Y, Liu N Front Oncol. 2022; 12:941347.

PMID: 36081566 PMC: 9445310. DOI: 10.3389/fonc.2022.941347.

Algorithm-Based Meta-Analysis Reveals the Mechanistic Interaction of the Tumor Suppressor LIMD1 With Non-Small-Cell Lung Carcinoma.

Wang L, Sparks-Wallace A, Casteel J, Howell M, Ning S Front Oncol. 2021; 11:632638.

PMID: 33869018 PMC: 8044451. DOI: 10.3389/fonc.2021.632638.

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.

Pineda B, Diaz-Lagares A, Perez-Fidalgo J, Burgues O, Gonzalez-Barrallo I, Crujeiras A Clin Epigenetics. 2019; 11(1):33.

PMID: 30786922 PMC: 6381754. DOI: 10.1186/s13148-019-0626-0.

A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology.

Michaelsen T, Richter J, Brondum R, Klapper W, Johnsen H, Albertsen M Blood Adv. 2018; 2(13):1542-1546.

PMID: 29967255 PMC: 6039667. DOI: 10.1182/bloodadvances.2018017988.

References

Kiss H, Kedra D, Yang Y, Kost-Alimova M, Kiss C, OBrien K . A novel gene containing LIM domains (LIMD1) is located within the common eliminated region 1 (C3CER1) in 3p21.3. Hum Genet. 2000; 105(6):552-9. DOI: 10.1007/s004399900188. View

Scott D, Wright G, Williams P, Lih C, Walsh W, Jaffe E . Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014; 123(8):1214-7. PMC: 3931191. DOI: 10.1182/blood-2013-11-536433. View

Heckman C, Mehew J, Ying G, Introna M, Golay J, Boxer L . A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. J Biol Chem. 2000; 275(9):6499-508. DOI: 10.1074/jbc.275.9.6499. View

Arsura M, Hofmann C, Golay J, Introna M, Sonenshein G . A-myb rescues murine B-cell lymphomas from IgM-receptor-mediated apoptosis through c-myc transcriptional regulation. Blood. 2000; 96(3):1013-20. View

Rosenwald A, Wright G, Chan W, Connors J, Campo E, Fisher R . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-47. DOI: 10.1056/NEJMoa012914. View

Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64. DOI: 10.1093/biostatistics/4.2.249. View

Wright G, Tan B, Rosenwald A, Hurt E, Wiestner A, Staudt L . A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003; 100(17):9991-6. PMC: 187912. DOI: 10.1073/pnas.1732008100. View

Pencina M, DAgostino R . Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004; 23(13):2109-23. DOI: 10.1002/sim.1802. View

Rhodes D, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D . Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A. 2004; 101(25):9309-14. PMC: 438973. DOI: 10.1073/pnas.0401994101. View

10.

Barletta C, Druck T, LaForgia S, Calabretta B, Drabkin H, Patterson D . Chromosome locations of the MYB related genes, AMYB and BMYB. Cancer Res. 1991; 51(14):3821-4. View

11.

Golay J, Luppi M, Songia S, Palvarini C, Lombardi L, Aiello A . Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. Blood. 1996; 87(5):1900-11. View

12.

Golay J, Basilico L, Loffarelli L, Songia S, Broccoli V, Introna M . Regulation of hematopoietic cell proliferation and differentiation by the myb oncogene family of transcription factors. Int J Clin Lab Res. 1996; 26(1):24-32. DOI: 10.1007/BF02644770. View

13.

Golay J, Broccoli V, Lamorte G, Bifulco C, Parravicini C, Pizzey A . The A-Myb transcription factor is a marker of centroblasts in vivo. J Immunol. 1998; 160(6):2786-93. View

14.

Sharp T, Munoz F, Bourboulia D, Presneau N, Darai E, Wang H . LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. Proc Natl Acad Sci U S A. 2004; 101(47):16531-6. PMC: 534532. DOI: 10.1073/pnas.0407123101. View

15.

Monti S, Savage K, Kutok J, Feuerhake F, Kurtin P, Mihm M . Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2004; 105(5):1851-61. DOI: 10.1182/blood-2004-07-2947. View

16.

Feng Y, Longmore G . The LIM protein Ajuba influences interleukin-1-induced NF-kappaB activation by affecting the assembly and activity of the protein kinase Czeta/p62/TRAF6 signaling complex. Mol Cell Biol. 2005; 25(10):4010-22. PMC: 1087715. DOI: 10.1128/MCB.25.10.4010-4022.2005. View

17.

Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth T . A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006; 354(23):2419-30. DOI: 10.1056/NEJMoa055351. View

18.

Reimers M, Carey V . Bioconductor: an open source framework for bioinformatics and computational biology. Methods Enzymol. 2006; 411:119-34. DOI: 10.1016/S0076-6879(06)11008-3. View

19.

Feng Y, Zhao H, Luderer H, Epple H, Faccio R, Ross F . The LIM protein, Limd1, regulates AP-1 activation through an interaction with Traf6 to influence osteoclast development. J Biol Chem. 2006; 282(1):39-48. DOI: 10.1074/jbc.M607399200. View

20.

de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A . Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007; 25(7):805-12. DOI: 10.1200/JCO.2006.09.4490. View